SCHEMBL458060

SCHEMBL458060

CCOc1ccccc1C=CC(=O)NN

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.58
▸ MAPT P10636 1/20 0.58
▸ ATM Q13315 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ NPC1 O15118 1/20 0.53
▸ EGFR P00533 1/20 0.52
▸ AR P10275 1/20 0.52
▸ NFE2L2 Q16236 2/20 0.51
▸ MCL1 Q07820 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ HDAC3 O15379 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC7 Q8WUI4 2/20 0.48
▸ HDAC2 Q92769 2/20 0.48
▸ HDAC10 Q969S8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458059 1.00 LMNA (0.58) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL5698607 0.87 NFE2L2 (0.49) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL5434722 0.86 LMNA (0.55) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL30071741 0.86 LMNA (0.55) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL5434717 0.86 LMNA (0.55) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL459849 0.83 LMNA (0.53) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL20446704 0.83 LMNA (0.62) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL28300287 0.83 LMNA (0.62) LMNAMAPTATMSMN1; SMN2NPC1
SCHEMBL458477 0.83 NFE2L2 (0.69) LMNAMAPTATMNPC1AR
SCHEMBL458476 0.83 NFE2L2 (0.69) LMNAMAPTATMNPC1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853276-B2 Guanidine derivatives in cinnamic series PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2014-10-07 — — US disclosed
EP-2614046-B1 NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) 2014-08-20 — — EP disclosed
EP-2614046-A1 NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES Produits Chimiques Auxiliaires et de Synthese (FR) 2013-07-17 — — EP disclosed
US-20130165507-A1 NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2013-06-27 — — US disclosed
WO-2012032257-A1 NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2012-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165507-A1 NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES GMPS, UNG, AGER LMNA 733/4885MAPT 2457/4885ATM 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback